FN2 Earnings Intelligence
Insmed Incorporated financials
Insmed Incorporated (INSM) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $716.8 | $1,074 | $482.4 | $555 | $510.4 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $188.5 | $245.4 | $305.2 | $363.7 | $606.4 |
| % Growth | 14.6% | 30.2% | 24.4% | 19.2% | 66.7% |
| Gross Profit | $144.3 | $190.2 | $239.6 | $278 | $483.5 |
| % Margin | 76.6% | 77.5% | 78.5% | 76.4% | 79.7% |
| EBITDA | -$366 | -$452 | -$704.1 | -$872.3 | -$1,236.3 |
| % Margin | -194.2% | -184.2% | -230.7% | -239.8% | -203.9% |
| Net Income | -$434.7 | -$481.5 | -$749.6 | -$913.8 | -$1,276.8 |
| % Margin | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| Diluted EPS | -$3.88 | -$3.91 | -$5.34 | -$5.57 | -$6.42 |
| % Growth | - | -0.8% | -36.6% | -4.3% | -15.3% |
| Operating Cash Flow | -$363.3 | -$400.4 | -$536.2 | -$683.9 | -$935 |
| CapEx | $7.3 | $9.9 | $13.3 | $21.9 | $32.6 |
| Free Cash Flow | -$370.6 | -$410.3 | -$549.5 | -$705.8 | -$967.6 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $188.5 | $245.4 | $305.2 | $363.7 | $606.4 |
| Gross Profit | $144.3 | $190.2 | $239.6 | $278 | $483.5 |
| EBITDA | -$366 | -$452 | -$704.1 | -$872.3 | -$1,236.3 |
| Net Income | -$434.7 | -$481.5 | -$749.6 | -$913.8 | -$1,276.8 |
| Diluted EPS | -$3.88 | -$3.91 | -$5.34 | -$5.57 | -$6.42 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $716.8 | $1,074 | $482.4 | $555 | $510.4 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $566.6 | $1,125.2 | $1,155.3 | $1,103.4 | $541 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$363.3 | -$400.4 | -$536.2 | -$683.9 | -$935 |
| Capital Expenditure | $7.3 | $9.9 | $13.3 | $21.9 | $32.6 |
| Free Cash Flow | -$370.6 | -$410.3 | -$549.5 | -$705.8 | -$967.6 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 14.6% | 30.2% | 24.4% | 19.2% | 66.7% |
| Gross Margin | 76.6% | 77.5% | 78.5% | 76.4% | 79.7% |
| EBITDA Margin | -194.2% | -184.2% | -230.7% | -239.8% | -203.9% |
| Net Margin | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| FCF Margin | -196.6% | -167.2% | -180.1% | -194.1% | -159.6% |
| Diluted EPS Growth | - | -0.8% | -36.6% | -4.3% | -15.3% |
Get the INSM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.